β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy

Neurology

Volumn 88, Issue 2, 2017, Pages 169-176

  Van Etten, Ellis S ^a   Verbeek, Marcel M ^b   Van Der Grond, Jeroen ^a   Zielman, Ronald ^a   Van Rooden, Sanneke ^a   Van Zwet, Erik W ^a   Van Opstal, Anna M ^a   Haan, Joost ^a,c   Greenberg, Steven M ^d   Van Buchem, Mark A ^a   Wermer, Marieke J H ^a   Terwindt, Gisela M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c ALRIJNE HOSPITAL   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GLUCOSE; LACTIC ACID; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC SCREENING; HEREDITARY CEREBRAL HEMORRHAGE WITH AMYLOIDOSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDEROSIS; VASCULAR AMYLOIDOSIS; WHITE MATTER; CEREBRAL AMYLOID ANGIOPATHY; DIAGNOSTIC IMAGING; MIDDLE AGED; NONPARAMETRIC TEST; YOUNG ADULT;

ADULT; AMYLOID BETA-PEPTIDES; ASYMPTOMATIC DISEASES; BIOMARKERS; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 85009060652     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003486     Document Type: Article

References (34)

1. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011;70:871-880.
2. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-539.
3. Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998;51: 690-694.
4. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012;83:124-137.
5. Maat-Schieman ML, van Duinen SG, Bornebroek M, Haan J, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), II: a review of histopathological aspects. Brain Pathol 1996;6:115-120.
6. Bakker E, van Broeckhoven C, Haan J, et al. DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type). Am J Hum Genet 1991;49:518-521.
7. Herzig MC, Winkler DT, Burgermeister P, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004;7:954-960.
8. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke 2009;40:2601-2606.
9. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med 2007;45:1421-1434.
10. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009;66:245-249.
11. Renard D, Castelnovo G, Wacongne A, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol 2012;259:2429-2433.
12. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165-174.
13. Feldman HH, Maia LF, Mackenzie IR, Forster BB, Martzke J, Woolfenden A. Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. Stroke 2008;39:2894-2897.
14. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.
15. Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study. Stroke 2010;41:2483-2490.
16. Charidimou A, Boulouis G, Haley K, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2016;86:505-511.
17. Foster-Dingley JC, Moonen JE, van den Berg-Huijsmans AA, et al. Lower blood pressure and gray matter integrity loss in older persons. J Clin Hypertens 2015;17:630-637.
18. Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 2007;53:859-865.
19. Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain: implications for Alzheimer disease. Nat Rev Neurol 2015;11:457-470.
20. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011;37:75-93.
21. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253-266.
22. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16:30-39.
23. Shinkai Y, Yoshimura M, Ito Y, et al. Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra-and intracranial blood vessels. Ann Neurol 1995;38:421-428.
24. Natte R, Yamaguchi H, Maat-Schieman ML, et al. Ultrastructural evidence of early non-fibrillar Abeta42 in the capillary basement membrane of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type. Acta Neuropathol 1999;98:577-582.
25. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 1998;57:353-359.
26. Maat-Schieman ML, van Duinen SG, Rozemuller AJ, Haan J, Roos RA. Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J Neuropathol Exp Neurol 1997;56: 273-284.
27. Vinters HV, Secor DL, Read SL, et al. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct Pathol 1994;18:333-348.
28. Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 2006;16:40-54.
29. Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277:793-799.
30. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
31. Bornebroek M, Haan J, Maat-Schieman ML, Van Duinen SG, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), I: a review of clinical, radiologic and genetic aspects. Brain Pathol 1996;6: 111-114.
32. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97.
33. van Duinen SG, Castano EM, Prelli F, Bots GT, Luyendijk W, Frangione B. Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci USA 1987;84:5991-5994.
34. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani O, Frangione B. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest 1990;62:761-767.